SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'VGH'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1M17_A_AQ4A999_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 ALA A1978 LYS A1980 LEU A2028 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.35A	1m17A-3zbfA: 27.6	1m17A-3zbfA: 34.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1MUO_A_ADNA1_1 (AURORA-RELATED KINASE 1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 9	LEU A1951 GLY A1952 VAL A1959 ALA A1978 LEU A2010 LEU A2086	VGH A3000 ( 4.4A) None None VGH A3000 (-3.4A) VGH A3000 (-4.8A) VGH A3000 (-4.3A)	1.06A	1muoA-3zbfA: 18.8	1muoA-3zbfA: 26.10
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 6	LEU A1951 LYS A1980 ILE A2024 MET A2029	VGH A3000 ( 4.4A) VGH A3000 ( 4.7A) None None	0.87A	1opjB-3zbfA: 24.6	1opjB-3zbfA: 38.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWH_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	ALA A1978 LYS A1980 LEU A2010 LEU A2070 HIS A2077 GLY A2101	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) None None VGH A3000 (-3.5A)	0.80A	1uwhB-3zbfA: 19.0	1uwhB-3zbfA: 30.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_A_BAXA1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LEU A2010 LEU A2070 HIS A2077 GLY A2101	None VGH A3000 (-3.4A) VGH A3000 (-4.8A) None None VGH A3000 (-3.5A)	0.82A	1uwjA-3zbfA: 10.4	1uwjA-3zbfA: 30.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1UWJ_B_BAXB1723_1 (B-RAF PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LEU A2010 LEU A2070 HIS A2077 GLY A2101	None VGH A3000 (-3.4A) VGH A3000 (-4.8A) None None VGH A3000 (-3.5A)	0.82A	1uwjB-3zbfA: 10.4	1uwjB-3zbfA: 30.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XBB_A_STIA1_1 (TYROSINE-PROTEIN KINASE SYK)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 9	LEU A1951 VAL A1959 ALA A1978 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.31A	1xbbA-3zbfA: 28.9	1xbbA-3zbfA: 33.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1XKK_A_FMMA91_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	GLY A2032 LEU A2035 ARG A2039 LEU A2086 ASP A2102 PHE A2103	VGH A3000 (-3.5A) None None VGH A3000 (-4.3A) None None	0.90A	1xkkA-3zbfA: 24.5	1xkkA-3zbfA: 38.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2GQG_A_1N1A501_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 ALA A1978 LYS A1980 MET A2001 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.63A	2gqgA-3zbfA: 28.9	2gqgA-3zbfA: 39.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITO_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	LEU A1951 ALA A1978 LYS A1980 MET A2001 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.74A	2itoA-3zbfA: 26.1	2itoA-3zbfA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 12	LEU A1951 GLY A1952 VAL A1959 ALA A1978 LYS A1980 GLU A1997 MET A2001 GLY A2032 ASP A2102	VGH A3000 ( 4.4A) None None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None VGH A3000 (-3.5A) None	0.81A	2ityA-3zbfA: 28.6	2ityA-3zbfA: 33.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITY_A_IREA2020_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 12	LEU A1951 GLY A1952 VAL A1959 ALA A1978 LYS A1980 MET A2001 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.69A	2ityA-3zbfA: 28.6	2ityA-3zbfA: 33.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 MET A2001 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.75A	2itzA-3zbfA: 28.6	2itzA-3zbfA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ITZ_A_IREA2021_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 LYS A1980 GLU A1997 MET A2001 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 ( 4.7A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.94A	2itzA-3zbfA: 28.6	2itzA-3zbfA: 33.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2WGJ_A_VGHA2346_1 (HEPATOCYTE GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	VAL A1959 ALA A1978 LEU A2010 LEU A2026 MET A2029 GLY A2032 ASP A2102	None VGH A3000 (-3.4A) VGH A3000 (-4.8A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) None	0.47A	2wgjA-3zbfA: 30.4	2wgjA-3zbfA: 37.58
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2XP2_A_VGHA9000_1 (TYROSINE-PROTEIN KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 9	LEU A1951 VAL A1959 ALA A1978 LEU A2026 MET A2029 GLY A2032 LEU A2086 GLY A2101 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A) None	0.35A	2xp2A-3zbfA: 34.7	2xp2A-3zbfA: 48.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_A_B49A1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.65A	2y7jA-3zbfA: 25.6	2y7jA-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_A_B49A1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.45A	2y7jA-3zbfA: 25.6	2y7jA-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 10	ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.64A	2y7jB-3zbfA: 21.0	2y7jB-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 10	VAL A1959 ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.38A	2y7jB-3zbfA: 21.0	2y7jB-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_C_B49C1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 10	VAL A1959 ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.42A	2y7jC-3zbfA: 21.2	2y7jC-3zbfA: 24.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_D_B49D1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 10	VAL A1959 ALA A1978 LEU A2028 MET A2029 GLY A2032 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.35A	2y7jD-3zbfA: 25.9	2y7jD-3zbfA: 24.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ZVA_A_1N1A513_1 (TYROSINE-PROTEIN KINASE LYN)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 ALA A1978 LYS A1980 MET A2001 ILE A2024 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.50A	2zvaA-3zbfA: 26.3	2zvaA-3zbfA: 38.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 10	ALA A1978 LEU A2026 LEU A2028 MET A2029 GLY A2031 LEU A2086	VGH A3000 (-3.4A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) None None VGH A3000 (-4.3A)	0.90A	3aoxA-3zbfA: 33.8	3aoxA-3zbfA: 45.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 10	LEU A1951 ALA A1978 LEU A2026 LEU A2028 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.44A	3aoxA-3zbfA: 33.8	3aoxA-3zbfA: 45.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 10	LEU A1951 ALA A1978 LYS A1980 LEU A2026 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.54A	3aoxA-3zbfA: 33.8	3aoxA-3zbfA: 45.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 9	LEU A1951 VAL A1959 ILE A2024 PHE A2075 LEU A2086	VGH A3000 ( 4.4A) None None None VGH A3000 (-4.3A)	0.81A	3cs9B-3zbfA: 26.0	3cs9B-3zbfA: 39.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 9	LEU A1951 VAL A1959 LYS A1980 ILE A2024 PHE A2075	VGH A3000 ( 4.4A) None VGH A3000 ( 4.7A) None None	0.93A	3cs9B-3zbfA: 26.0	3cs9B-3zbfA: 39.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K54_A_1N1A1_1 (TYROSINE-PROTEIN KINASE BTK)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 ALA A1978 LYS A1980 MET A2001 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.64A	3k54A-3zbfA: 26.9	3k54A-3zbfA: 36.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3MIY_B_B49B2_1 (TYROSINE-PROTEIN KINASE ITK/TSK)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 9	ALA A1978 LYS A1980 MET A2029 GLY A2032 LEU A2086	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.55A	3miyB-3zbfA: 32.8	3miyB-3zbfA: 37.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 9	LEU A1951 LYS A1980 ILE A2024 MET A2029 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 ( 4.7A) None None VGH A3000 (-4.3A)	0.79A	3oxzA-3zbfA: 31.1	3oxzA-3zbfA: 40.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SXR_A_1N1A1_1 (CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 MET A2001 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.80A	3sxrA-3zbfA: 25.2	3sxrA-3zbfA: 39.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 ALA A1978 LYS A1980 GLU A1997 ILE A2024 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.62A	3ue4A-3zbfA: 33.4	3ue4A-3zbfA: 37.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 GLU A1997 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.78A	3ue4B-3zbfA: 26.5	3ue4B-3zbfA: 37.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UE4_B_DB8B601_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 GLU A1997 MET A2001 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.83A	3ue4B-3zbfA: 26.5	3ue4B-3zbfA: 37.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 LEU A2028 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.54A	3ug2A-3zbfA: 27.3	3ug2A-3zbfA: 34.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3V5W_A_8PRA701_2 (G-PROTEIN COUPLED RECEPTOR KINASE 2)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	3 / 3	LEU A2026 MET A2029 ASP A2033	VGH A3000 ( 4.2A) None VGH A3000 (-4.5A)	0.60A	3v5wA-3zbfA: 7.5	3v5wA-3zbfA: 18.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANQ_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 9	LEU A1951 VAL A1959 ALA A1978 LEU A2026 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.34A	4anqA-3zbfA: 34.5	4anqA-3zbfA: 49.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 9	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.33A	4ansA-3zbfA: 34.4	4ansA-3zbfA: 49.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4CSV_A_STIA1265_2 (SRC-ABL TYROSINE KINASE ANCESTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 4	LYS A1980 ILE A2024 MET A2029 PHE A2075	VGH A3000 ( 4.7A) None None None	0.80A	4csvA-3zbfA: 25.9	4csvA-3zbfA: 41.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HJO_A_AQ4A1001_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.51A	4hjoA-3zbfA: 29.7	4hjoA-3zbfA: 35.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAA_A_RTZA401_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 11	VAL A1959 ALA A1978 LYS A1980 LEU A2026 ASP A2033 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) VGH A3000 (-4.5A) VGH A3000 (-4.3A)	0.85A	4iaaA-3zbfA: 17.5	4iaaA-3zbfA: 25.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4IAA_A_RTZA401_1 (SERINE/THREONINE-PRO TEIN KINASE PIM-1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 11	VAL A1959 ALA A1978 LYS A1980 LEU A2026 ASP A2102	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) None	0.62A	4iaaA-3zbfA: 17.5	4iaaA-3zbfA: 25.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 GLY A1957 VAL A1959 ALA A1978 LYS A1980 LEU A2026 LEU A2028	VGH A3000 ( 4.4A) None None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A)	1.22A	4mkcA-3zbfA: 34.0	4mkcA-3zbfA: 45.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MKC_A_4MKA1503_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	10 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 LEU A2026 LEU A2028 GLY A2032 ASP A2033 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.5A) VGH A3000 (-4.3A) None	0.55A	4mkcA-3zbfA: 34.0	4mkcA-3zbfA: 45.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 MET A2001 ILE A2024 GLY A2032 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None VGH A3000 (-3.5A) None	0.64A	4mxoA-3zbfA: 26.4	4mxoA-3zbfA: 40.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXO_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 ILE A2024 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.55A	4mxoB-3zbfA: 26.4	4mxoB-3zbfA: 40.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXX_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 ALA A1978 LYS A1980 GLU A1997 MET A2001 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.90A	4mxxA-3zbfA: 26.1	4mxxA-3zbfA: 40.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXY_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 ILE A2024 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.57A	4mxyA-3zbfA: 32.8	4mxyA-3zbfA: 40.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXY_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.52A	4mxyB-3zbfA: 28.2	4mxyB-3zbfA: 40.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXZ_A_DB8A601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 ILE A2024 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.57A	4mxzA-3zbfA: 32.8	4mxzA-3zbfA: 40.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4MXZ_B_DB8B601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.52A	4mxzB-3zbfA: 28.2	4mxzB-3zbfA: 40.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4O0U_A_ADNA501_1 (AURORA KINASE A)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 6	VAL A1959 ALA A1978 LEU A2010 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 (-4.8A) VGH A3000 (-4.3A)	0.43A	4o0uA-3zbfA: 18.9	4o0uA-3zbfA: 27.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 12	ALA A1978 LYS A1980 LEU A2010 GLY A2101 PHE A2103	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) None	0.97A	4rzvA-3zbfA: 10.5	4rzvA-3zbfA: 30.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RZV_A_032A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 12	ALA A1978 LYS A1980 LEU A2010 ILE A2024 GLY A2101	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) None VGH A3000 (-3.5A)	0.74A	4rzvA-3zbfA: 10.5	4rzvA-3zbfA: 30.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_A_AXIA601_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	VAL A1959 ALA A1978 LYS A1980 MET A2029 GLY A2032 ASN A2084 LEU A2086 ASP A2102	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) None VGH A3000 (-4.3A) None	0.78A	4twpA-3zbfA: 27.0	4twpA-3zbfA: 39.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.87A	4twpB-3zbfA: 33.7	4twpB-3zbfA: 39.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4TWP_B_AXIB601_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	VAL A1959 ALA A1978 LYS A1980 MET A2029 GLY A2032 ASN A2084 LEU A2086 ASP A2102	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) None VGH A3000 (-4.3A) None	0.80A	4twpB-3zbfA: 33.7	4twpB-3zbfA: 39.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_A_RXTA601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 11	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 ASN A2084 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None VGH A3000 (-3.5A) None VGH A3000 (-4.3A) None	0.65A	4u5jA-3zbfA: 26.2	4u5jA-3zbfA: 40.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4U5J_B_RXTB601_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 9	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.61A	4u5jB-3zbfA: 26.2	4u5jB-3zbfA: 40.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_A_AXIA9000_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 11	LEU A1951 ALA A1978 MET A2029 GLY A2032 ASN A2084 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) None VGH A3000 (-3.5A) None VGH A3000 (-4.3A)	0.46A	4wa9A-3zbfA: 29.3	4wa9A-3zbfA: 40.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WA9_B_AXIB9000_1 (TYROSINE-PROTEIN KINASE ABL1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	VAL A1959 ALA A1978 LYS A1980 MET A2029 GLY A2032 ASN A2084 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 (-3.5A) None VGH A3000 (-4.3A)	0.99A	4wa9B-3zbfA: 26.6	4wa9B-3zbfA: 40.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 6	LEU A1951 ALA A1978 MET A2029 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) None VGH A3000 (-4.3A)	0.60A	4wboC-3zbfA: 22.6	4wboC-3zbfA: 19.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4WKQ_A_IREA1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 ALA A1978 LYS A1980 MET A2001 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.63A	4wkqA-3zbfA: 32.7	4wkqA-3zbfA: 34.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XLI_B_1N1B600_1 (NON-SPECIFIC PROTEIN-TYROSINE KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 ALA A1978 LYS A1980 MET A2001 ILE A2024 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.63A	4xliB-3zbfA: 28.8	4xliB-3zbfA: 39.74
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XOY_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 6	ALA A1978 LEU A2028 MET A2029 LEU A2086	VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-4.3A)	0.22A	4xoyA-3zbfA: 12.8	4xoyA-3zbfA: 27.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XP3_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 6	ALA A1978 LEU A2028 MET A2029 LEU A2086	VGH A3000 (-3.4A) VGH A3000 ( 4.8A) None VGH A3000 (-4.3A)	0.29A	4xp3A-3zbfA: 23.4	4xp3A-3zbfA: 27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	ALA A1978 LYS A1980 LEU A2010 GLY A2101 ASP A2102 PHE A2103	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) None None	0.85A	4xv2A-3zbfA: 22.3	4xv2A-3zbfA: 31.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LYS A1980 LEU A2010 GLY A2101 PHE A2103	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) None	0.85A	4xv2A-3zbfA: 22.3	4xv2A-3zbfA: 31.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4XV2_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	ALA A1978 LYS A1980 LEU A2010 GLY A2101 ASP A2102 PHE A2103	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) None None	0.80A	4xv2B-3zbfA: 28.3	4xv2B-3zbfA: 31.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAA_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 9	LEU A1951 VAL A1959 ALA A1978 LEU A2026 MET A2029 GLY A2032 LEU A2086 GLY A2101 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A) None	0.34A	5aaaA-3zbfA: 34.5	5aaaA-3zbfA: 47.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAB_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	10 / 10	LEU A1951 VAL A1959 ALA A1978 LYS A1980 LEU A2026 MET A2029 GLY A2032 LEU A2086 GLY A2101 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A) None	0.51A	5aabA-3zbfA: 34.4	5aabA-3zbfA: 47.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 10	LEU A1951 ALA A1978 LYS A1980 LEU A2026 MET A2029 GLY A2032 LEU A2086 GLY A2101	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A)	0.62A	5aacA-3zbfA: 34.7	5aacA-3zbfA: 48.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5AAC_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 10	LEU A1951 VAL A1959 ALA A1978 LEU A2026 MET A2029 GLY A2032 LEU A2086 GLY A2101 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.2A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A) None	0.41A	5aacA-3zbfA: 34.7	5aacA-3zbfA: 48.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 12	ALA A1978 LYS A1980 LEU A2010 GLY A2101 PHE A2103	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) None	0.78A	5cswA-3zbfA: 22.5	5cswA-3zbfA: 30.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	5 / 12	VAL A1959 ALA A1978 LYS A1980 LEU A2010 GLY A2101	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A)	0.73A	5cswA-3zbfA: 22.5	5cswA-3zbfA: 30.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5CSW_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LYS A1980 LEU A2010 GLY A2101 PHE A2103	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) None	0.92A	5cswB-3zbfA: 22.4	5cswB-3zbfA: 30.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5E72_A_SAMA400_1 (N2, N2-DIMETHYLGUANOSINE TRNA METHYLTRANSFERASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	4 / 4	ASP A2079 GLY A2104 ASP A2102 ASP A2033	None None None VGH A3000 (-4.5A)	1.06A	5e72A-3zbfA: undetectable	5e72A-3zbfA: 21.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	ALA A1978 LEU A2010 LEU A2028 GLY A2031 LEU A2086 GLY A2101	VGH A3000 (-3.4A) VGH A3000 (-4.8A) VGH A3000 ( 4.8A) None VGH A3000 (-4.3A) VGH A3000 (-3.5A)	0.82A	5h2uA-3zbfA: 28.9	5h2uA-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_A_1N1A501_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	LEU A1951 VAL A1959 ALA A1978 LEU A2010 LEU A2028 GLY A2032 LEU A2086 GLY A2101	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 (-4.8A) VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A)	0.63A	5h2uA-3zbfA: 28.9	5h2uA-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	ALA A1978 LEU A2010 ILE A2024 LEU A2028 GLY A2031 LEU A2086 GLY A2101	VGH A3000 (-3.4A) VGH A3000 (-4.8A) None VGH A3000 ( 4.8A) None VGH A3000 (-4.3A) VGH A3000 (-3.5A)	1.03A	5h2uB-3zbfA: 25.2	5h2uB-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	LEU A1951 LEU A2010 GLY A2032 LEU A2086 GLY A2101 ASP A2102	VGH A3000 ( 4.4A) VGH A3000 (-4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A) None	0.75A	5h2uB-3zbfA: 25.2	5h2uB-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 12	LEU A1951 VAL A1959 ALA A1978 LEU A2010 ILE A2024 LEU A2028 GLY A2032 LEU A2086 GLY A2101	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 (-4.8A) None VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A)	0.66A	5h2uB-3zbfA: 25.2	5h2uB-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_C_1N1C501_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 ALA A1978 LEU A2010 ILE A2024 GLY A2032 LEU A2086 GLY A2101	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 (-4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A)	0.65A	5h2uC-3zbfA: 29.1	5h2uC-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5H2U_D_1N1D504_1 (PROTEIN-TYROSINE KINASE 6)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	9 / 12	LEU A1951 VAL A1959 ALA A1978 LEU A2010 ILE A2024 LEU A2028 GLY A2032 LEU A2086 GLY A2101	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 (-4.8A) None VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A) VGH A3000 (-3.5A)	0.64A	5h2uD-3zbfA: 25.2	5h2uD-3zbfA: 36.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HI2_A_BAXA801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	ALA A1978 LYS A1980 LEU A2010 LEU A2070 HIS A2077 GLY A2101	VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) None None VGH A3000 (-3.5A)	0.78A	5hi2A-3zbfA: 19.6	5hi2A-3zbfA: 31.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_A_P06A801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LYS A1980 LEU A2010 ILE A2024 GLY A2101	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) None VGH A3000 (-3.5A)	0.73A	5hieA-3zbfA: 10.7	5hieA-3zbfA: 32.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_B_P06B801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LYS A1980 LEU A2010 ILE A2024 GLY A2101	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) None VGH A3000 (-3.5A)	0.74A	5hieB-3zbfA: 10.7	5hieB-3zbfA: 32.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5HIE_D_P06D801_1 (SERINE/THREONINE-PRO TEIN KINASE B-RAF)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	6 / 12	VAL A1959 ALA A1978 LYS A1980 LEU A2010 ILE A2024 GLY A2101	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 (-4.8A) None VGH A3000 (-3.5A)	0.75A	5hieD-3zbfA: 26.4	5hieD-3zbfA: 32.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.89A	5y7zA-3zbfA: 23.7	5y7zA-3zbfA: 12.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 ALA A1978 LYS A1980 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.89A	5y7zA-3zbfA: 23.7	5y7zA-3zbfA: 28.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 LYS A1980 GLU A1997 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 ( 4.7A) None VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	1.01A	5y7zA-3zbfA: 23.7	5y7zA-3zbfA: 12.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5Y7Z_A_IREA401_0 (CYCLIN-G-ASSOCIATED KINASE)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	7 / 12	LEU A1951 VAL A1959 LYS A1980 GLU A1997 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) None VGH A3000 ( 4.7A) None VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	1.01A	5y7zA-3zbfA: 23.7	5y7zA-3zbfA: 28.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZV2_A_LEVA801_2 (FIBROBLAST GROWTH FACTOR RECEPTOR 1)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	3 / 3	LYS A1980 LEU A2086 ASP A2102	VGH A3000 ( 4.7A) VGH A3000 (-4.3A) None	0.89A	5zv2A-3zbfA: 31.7	5zv2A-3zbfA: 16.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6FNM_A_1N1A1001_1 (-)	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	8 / 12	VAL A1959 ALA A1978 LYS A1980 MET A2001 ILE A2024 MET A2029 GLY A2032 LEU A2086	None VGH A3000 (-3.4A) VGH A3000 ( 4.7A) None None None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.90A	6fnmA-3zbfA: 28.3	6fnmA-3zbfA: 35.89

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1M17_A_AQ4A999_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LYS A1980;LEU A2028;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.35A","1m17A-3zbfA:27.6",null],["1MUO_A_ADNA1_1","AURORA-RELATED KINASE 1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"LEU A1951;GLY A1952;VAL A1959;ALA A1978;LEU A2010;LEU A2086","VGH A3000 ( 4.4A);None;None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);VGH A3000 (-4.3A)","1.06A","1muoA-3zbfA:18.8","1m17A-3zbfA:34.08"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"LEU A1951;LYS A1980;ILE A2024;MET A2029","VGH A3000 ( 4.4A);VGH A3000 ( 4.7A);None;None","0.87A","1opjB-3zbfA:24.6","1muoA-3zbfA:26.10"],["1UWH_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LYS A1980;LEU A2010;LEU A2070;HIS A2077;GLY A2101","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);None;None;VGH A3000 (-3.5A)","0.80A","1uwhB-3zbfA:19.0","1opjB-3zbfA:38.79"],["1UWJ_A_BAXA1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LEU A2010;LEU A2070;HIS A2077;GLY A2101","None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);None;None;VGH A3000 (-3.5A)","0.82A","1uwjA-3zbfA:10.4","1uwhB-3zbfA:30.32"],["1UWJ_B_BAXB1723_1","B-RAF PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LEU A2010;LEU A2070;HIS A2077;GLY A2101","None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);None;None;VGH A3000 (-3.5A)","0.82A","1uwjB-3zbfA:10.4","1uwjA-3zbfA:30.32"],["1XBB_A_STIA1_1","TYROSINE-PROTEIN KINASE SYK","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"LEU A1951;VAL A1959;ALA A1978;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.31A","1xbbA-3zbfA:28.9","1uwjB-3zbfA:30.32"],["1XKK_A_FMMA91_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"GLY A2032;LEU A2035;ARG A2039;LEU A2086;ASP A2102;PHE A2103","VGH A3000 (-3.5A);None;None;VGH A3000 (-4.3A);None;None","0.90A","1xkkA-3zbfA:24.5","1xbbA-3zbfA:33.44"],["2GQG_A_1N1A501_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LYS A1980;MET A2001;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.63A","2gqgA-3zbfA:28.9","1xkkA-3zbfA:38.92"],["2ITO_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"LEU A1951;ALA A1978;LYS A1980;MET A2001;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.74A","2itoA-3zbfA:26.1","2gqgA-3zbfA:39.68"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;GLY A1952;VAL A1959;ALA A1978;LYS A1980;GLU A1997;MET A2001;GLY A2032;ASP A2102","VGH A3000 ( 4.4A);None;None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;VGH A3000 (-3.5A);None","0.81A","2ityA-3zbfA:28.6","2itoA-3zbfA:33.52"],["2ITY_A_IREA2020_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;GLY A1952;VAL A1959;ALA A1978;LYS A1980;MET A2001;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.69A","2ityA-3zbfA:28.6","2ityA-3zbfA:33.80"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;MET A2001;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.75A","2itzA-3zbfA:28.6","2ityA-3zbfA:33.80"],["2ITZ_A_IREA2021_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;LYS A1980;GLU A1997;MET A2001;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 ( 4.7A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.94A","2itzA-3zbfA:28.6","2itzA-3zbfA:33.52"],["2WGJ_A_VGHA2346_1","HEPATOCYTE GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"VAL A1959;ALA A1978;LEU A2010;LEU A2026;MET A2029;GLY A2032;ASP A2102","None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);None","0.47A","2wgjA-3zbfA:30.4","2itzA-3zbfA:33.52"],["2XP2_A_VGHA9000_1","TYROSINE-PROTEIN KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;VAL A1959;ALA A1978;LEU A2026;MET A2029;GLY A2032;LEU A2086;GLY A2101;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A);None","0.35A","2xp2A-3zbfA:34.7","2wgjA-3zbfA:37.58"],["2Y7J_A_B49A1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.65A","2y7jA-3zbfA:25.6","2xp2A-3zbfA:48.20"],["2Y7J_A_B49A1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.45A","2y7jA-3zbfA:25.6","2y7jA-3zbfA:24.31"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.64A","2y7jB-3zbfA:21.0","2y7jA-3zbfA:24.31"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.38A","2y7jB-3zbfA:21.0","2y7jB-3zbfA:24.31"],["2Y7J_C_B49C1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.42A","2y7jC-3zbfA:21.2","2y7jB-3zbfA:24.31"],["2Y7J_D_B49D1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LEU A2028;MET A2029;GLY A2032;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.35A","2y7jD-3zbfA:25.9","2y7jC-3zbfA:24.31"],["2ZVA_A_1N1A513_1","TYROSINE-PROTEIN KINASE LYN","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;ALA A1978;LYS A1980;MET A2001;ILE A2024;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.50A","2zvaA-3zbfA:26.3","2y7jD-3zbfA:24.31"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LEU A2026;LEU A2028;MET A2029;GLY A2031;LEU A2086","VGH A3000 (-3.4A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);None;None;VGH A3000 (-4.3A)","0.90A","3aoxA-3zbfA:33.8","2zvaA-3zbfA:38.94"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LEU A2026;LEU A2028;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.44A","3aoxA-3zbfA:33.8","3aoxA-3zbfA:45.64"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LYS A1980;LEU A2026;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.54A","3aoxA-3zbfA:33.8","3aoxA-3zbfA:45.64"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"LEU A1951;VAL A1959;ILE A2024;PHE A2075;LEU A2086","VGH A3000 ( 4.4A);None;None;None;VGH A3000 (-4.3A)","0.81A","3cs9B-3zbfA:26.0","3aoxA-3zbfA:45.64"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"LEU A1951;VAL A1959;LYS A1980;ILE A2024;PHE A2075","VGH A3000 ( 4.4A);None;VGH A3000 ( 4.7A);None;None","0.93A","3cs9B-3zbfA:26.0","3cs9B-3zbfA:39.68"],["3K54_A_1N1A1_1","TYROSINE-PROTEIN KINASE BTK","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LYS A1980;MET A2001;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.64A","3k54A-3zbfA:26.9","3cs9B-3zbfA:39.68"],["3MIY_B_B49B2_1","TYROSINE-PROTEIN KINASE ITK\/TSK","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"ALA A1978;LYS A1980;MET A2029;GLY A2032;LEU A2086","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.55A","3miyB-3zbfA:32.8","3k54A-3zbfA:36.73"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"LEU A1951;LYS A1980;ILE A2024;MET A2029;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 ( 4.7A);None;None;VGH A3000 (-4.3A)","0.79A","3oxzA-3zbfA:31.1","3miyB-3zbfA:37.87"],["3SXR_A_1N1A1_1","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;MET A2001;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.80A","3sxrA-3zbfA:25.2","3oxzA-3zbfA:40.06"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;ALA A1978;LYS A1980;GLU A1997;ILE A2024;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.62A","3ue4A-3zbfA:33.4","3sxrA-3zbfA:39.93"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;GLU A1997;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.78A","3ue4B-3zbfA:26.5","3ue4A-3zbfA:37.92"],["3UE4_B_DB8B601_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;GLU A1997;MET A2001;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.83A","3ue4B-3zbfA:26.5","3ue4B-3zbfA:37.92"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;LEU A2028;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.54A","3ug2A-3zbfA:27.3","3ue4B-3zbfA:37.92"],["3V5W_A_8PRA701_2","G-PROTEIN COUPLED RECEPTOR KINASE 2","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",3,"LEU A2026;MET A2029;ASP A2033","VGH A3000 ( 4.2A);None;VGH A3000 (-4.5A)","0.60A","3v5wA-3zbfA:7.5","3ug2A-3zbfA:34.08"],["4ANQ_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LEU A2026;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.34A","4anqA-3zbfA:34.5","3v5wA-3zbfA:18.52"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.33A","4ansA-3zbfA:34.4","4anqA-3zbfA:49.56"],["4CSV_A_STIA1265_2","SRC-ABL TYROSINE KINASE ANCESTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"LYS A1980;ILE A2024;MET A2029;PHE A2075","VGH A3000 ( 4.7A);None;None;None","0.80A","4csvA-3zbfA:25.9","4ansA-3zbfA:49.27"],["4HJO_A_AQ4A1001_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"LEU A1951;VAL A1959;ALA A1978;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.51A","4hjoA-3zbfA:29.7","4csvA-3zbfA:41.56"],["4IAA_A_RTZA401_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LYS A1980;LEU A2026;ASP A2033;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);VGH A3000 (-4.5A);VGH A3000 (-4.3A)","0.85A","4iaaA-3zbfA:17.5","4hjoA-3zbfA:35.20"],["4IAA_A_RTZA401_1","SERINE\/THREONINE-PROTEIN KINASE PIM-1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"VAL A1959;ALA A1978;LYS A1980;LEU A2026;ASP A2102","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);None","0.62A","4iaaA-3zbfA:17.5","4iaaA-3zbfA:25.44"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;GLY A1957;VAL A1959;ALA A1978;LYS A1980;LEU A2026;LEU A2028","VGH A3000 ( 4.4A);None;None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A)","1.22A","4mkcA-3zbfA:34.0","4iaaA-3zbfA:25.44"],["4MKC_A_4MKA1503_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",10,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;LEU A2026;LEU A2028;GLY A2032;ASP A2033;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.5A);VGH A3000 (-4.3A);None","0.55A","4mkcA-3zbfA:34.0","4mkcA-3zbfA:45.80"],["4MXO_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;MET A2001;ILE A2024;GLY A2032;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;VGH A3000 (-3.5A);None","0.64A","4mxoA-3zbfA:26.4","4mkcA-3zbfA:45.80"],["4MXO_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;ILE A2024;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.55A","4mxoB-3zbfA:26.4","4mxoA-3zbfA:40.38"],["4MXX_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;ALA A1978;LYS A1980;GLU A1997;MET A2001;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.90A","4mxxA-3zbfA:26.1","4mxoB-3zbfA:40.38"],["4MXY_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;ILE A2024;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.57A","4mxyA-3zbfA:32.8","4mxxA-3zbfA:40.38"],["4MXY_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.52A","4mxyB-3zbfA:28.2","4mxyA-3zbfA:40.06"],["4MXZ_A_DB8A601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;ILE A2024;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.57A","4mxzA-3zbfA:32.8","4mxyB-3zbfA:40.06"],["4MXZ_B_DB8B601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.52A","4mxzB-3zbfA:28.2","4mxzA-3zbfA:40.06"],["4O0U_A_ADNA501_1","AURORA KINASE A","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"VAL A1959;ALA A1978;LEU A2010;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);VGH A3000 (-4.3A)","0.43A","4o0uA-3zbfA:18.9","4mxzB-3zbfA:40.06"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"ALA A1978;LYS A1980;LEU A2010;GLY A2101;PHE A2103","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);None","0.97A","4rzvA-3zbfA:10.5","4o0uA-3zbfA:27.38"],["4RZV_A_032A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"ALA A1978;LYS A1980;LEU A2010;ILE A2024;GLY A2101","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);None;VGH A3000 (-3.5A)","0.74A","4rzvA-3zbfA:10.5","4rzvA-3zbfA:30.45"],["4TWP_A_AXIA601_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"VAL A1959;ALA A1978;LYS A1980;MET A2029;GLY A2032;ASN A2084;LEU A2086;ASP A2102","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);None;VGH A3000 (-4.3A);None","0.78A","4twpA-3zbfA:27.0","4rzvA-3zbfA:30.45"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.87A","4twpB-3zbfA:33.7","4twpA-3zbfA:39.55"],["4TWP_B_AXIB601_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"VAL A1959;ALA A1978;LYS A1980;MET A2029;GLY A2032;ASN A2084;LEU A2086;ASP A2102","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);None;VGH A3000 (-4.3A);None","0.80A","4twpB-3zbfA:33.7","4twpB-3zbfA:39.55"],["4U5J_A_RXTA601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;MET A2029;GLY A2032;ASN A2084;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);None;VGH A3000 (-4.3A);None","0.65A","4u5jA-3zbfA:26.2","4twpB-3zbfA:39.55"],["4U5J_B_RXTB601_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.61A","4u5jB-3zbfA:26.2","4u5jA-3zbfA:40.06"],["4WA9_A_AXIA9000_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"LEU A1951;ALA A1978;MET A2029;GLY A2032;ASN A2084;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);None;VGH A3000 (-4.3A)","0.46A","4wa9A-3zbfA:29.3","4u5jB-3zbfA:40.06"],["4WA9_B_AXIB9000_1","TYROSINE-PROTEIN KINASE ABL1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"VAL A1959;ALA A1978;LYS A1980;MET A2029;GLY A2032;ASN A2084;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 (-3.5A);None;VGH A3000 (-4.3A)","0.99A","4wa9B-3zbfA:26.6","4wa9A-3zbfA:40.26"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"LEU A1951;ALA A1978;MET A2029;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);None;VGH A3000 (-4.3A)","0.60A","4wboC-3zbfA:22.6","4wa9B-3zbfA:40.26"],["4WKQ_A_IREA1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LYS A1980;MET A2001;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.63A","4wkqA-3zbfA:32.7","4wboC-3zbfA:19.86"],["4XLI_B_1N1B600_1","NON-SPECIFIC PROTEIN-TYROSINE KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LYS A1980;MET A2001;ILE A2024;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.63A","4xliB-3zbfA:28.8","4wkqA-3zbfA:34.08"],["4XOY_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"ALA A1978;LEU A2028;MET A2029;LEU A2086","VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-4.3A)","0.22A","4xoyA-3zbfA:12.8","4xliB-3zbfA:39.74"],["4XP3_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"ALA A1978;LEU A2028;MET A2029;LEU A2086","VGH A3000 (-3.4A);VGH A3000 ( 4.8A);None;VGH A3000 (-4.3A)","0.29A","4xp3A-3zbfA:23.4","4xoyA-3zbfA:27.27"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LYS A1980;LEU A2010;GLY A2101;ASP A2102;PHE A2103","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);None;None","0.85A","4xv2A-3zbfA:22.3","4xp3A-3zbfA:27.27"],["4XV2_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LYS A1980;LEU A2010;GLY A2101;PHE A2103","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);None","0.85A","4xv2A-3zbfA:22.3","4xv2A-3zbfA:31.45"],["4XV2_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LYS A1980;LEU A2010;GLY A2101;ASP A2102;PHE A2103","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);None;None","0.80A","4xv2B-3zbfA:28.3","4xv2A-3zbfA:31.45"],["5AAA_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;VAL A1959;ALA A1978;LEU A2026;MET A2029;GLY A2032;LEU A2086;GLY A2101;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A);None","0.34A","5aaaA-3zbfA:34.5","4xv2B-3zbfA:31.45"],["5AAB_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",10,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;LEU A2026;MET A2029;GLY A2032;LEU A2086;GLY A2101;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A);None","0.51A","5aabA-3zbfA:34.4","5aaaA-3zbfA:47.90"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;ALA A1978;LYS A1980;LEU A2026;MET A2029;GLY A2032;LEU A2086;GLY A2101","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A)","0.62A","5aacA-3zbfA:34.7","5aabA-3zbfA:47.90"],["5AAC_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;VAL A1959;ALA A1978;LEU A2026;MET A2029;GLY A2032;LEU A2086;GLY A2101;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.2A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A);None","0.41A","5aacA-3zbfA:34.7","5aacA-3zbfA:48.20"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"ALA A1978;LYS A1980;LEU A2010;GLY A2101;PHE A2103","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);None","0.78A","5cswA-3zbfA:22.5","5aacA-3zbfA:48.20"],["5CSW_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",5,"VAL A1959;ALA A1978;LYS A1980;LEU A2010;GLY A2101","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A)","0.73A","5cswA-3zbfA:22.5","5cswA-3zbfA:30.45"],["5CSW_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LYS A1980;LEU A2010;GLY A2101;PHE A2103","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);None","0.92A","5cswB-3zbfA:22.4","5cswA-3zbfA:30.45"],["5E72_A_SAMA400_1","N2, N2-DIMETHYLGUANOSINE TRNA METHYLTRANSFERASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",4,"ASP A2079;GLY A2104;ASP A2102;ASP A2033","None;None;None;VGH A3000 (-4.5A)","1.06A","5e72A-3zbfA:undetectable","5cswB-3zbfA:30.45"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LEU A2010;LEU A2028;GLY A2031;LEU A2086;GLY A2101","VGH A3000 (-3.4A);VGH A3000 (-4.8A);VGH A3000 ( 4.8A);None;VGH A3000 (-4.3A);VGH A3000 (-3.5A)","0.82A","5h2uA-3zbfA:28.9","5e72A-3zbfA:21.24"],["5H2U_A_1N1A501_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"LEU A1951;VAL A1959;ALA A1978;LEU A2010;LEU A2028;GLY A2032;LEU A2086;GLY A2101","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A)","0.63A","5h2uA-3zbfA:28.9","5h2uA-3zbfA:36.84"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"ALA A1978;LEU A2010;ILE A2024;LEU A2028;GLY A2031;LEU A2086;GLY A2101","VGH A3000 (-3.4A);VGH A3000 (-4.8A);None;VGH A3000 ( 4.8A);None;VGH A3000 (-4.3A);VGH A3000 (-3.5A)","1.03A","5h2uB-3zbfA:25.2","5h2uA-3zbfA:36.84"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"LEU A1951;LEU A2010;GLY A2032;LEU A2086;GLY A2101;ASP A2102","VGH A3000 ( 4.4A);VGH A3000 (-4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A);None","0.75A","5h2uB-3zbfA:25.2","5h2uB-3zbfA:36.84"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;VAL A1959;ALA A1978;LEU A2010;ILE A2024;LEU A2028;GLY A2032;LEU A2086;GLY A2101","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);None;VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A)","0.66A","5h2uB-3zbfA:25.2","5h2uB-3zbfA:36.84"],["5H2U_C_1N1C501_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;ALA A1978;LEU A2010;ILE A2024;GLY A2032;LEU A2086;GLY A2101","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 (-4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A)","0.65A","5h2uC-3zbfA:29.1","5h2uB-3zbfA:36.84"],["5H2U_D_1N1D504_1","PROTEIN-TYROSINE KINASE 6","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",9,"LEU A1951;VAL A1959;ALA A1978;LEU A2010;ILE A2024;LEU A2028;GLY A2032;LEU A2086;GLY A2101","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 (-4.8A);None;VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A);VGH A3000 (-3.5A)","0.64A","5h2uD-3zbfA:25.2","5h2uC-3zbfA:36.84"],["5HI2_A_BAXA801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"ALA A1978;LYS A1980;LEU A2010;LEU A2070;HIS A2077;GLY A2101","VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);None;None;VGH A3000 (-3.5A)","0.78A","5hi2A-3zbfA:19.6","5h2uD-3zbfA:36.84"],["5HIE_A_P06A801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LYS A1980;LEU A2010;ILE A2024;GLY A2101","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);None;VGH A3000 (-3.5A)","0.73A","5hieA-3zbfA:10.7","5hi2A-3zbfA:31.56"],["5HIE_B_P06B801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LYS A1980;LEU A2010;ILE A2024;GLY A2101","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);None;VGH A3000 (-3.5A)","0.74A","5hieB-3zbfA:10.7","5hieA-3zbfA:32.36"],["5HIE_D_P06D801_1","SERINE\/THREONINE-PROTEIN KINASE B-RAF","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",6,"VAL A1959;ALA A1978;LYS A1980;LEU A2010;ILE A2024;GLY A2101","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 (-4.8A);None;VGH A3000 (-3.5A)","0.75A","5hieD-3zbfA:26.4","5hieB-3zbfA:32.36"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.89A","5y7zA-3zbfA:23.7","5hieD-3zbfA:32.36"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;ALA A1978;LYS A1980;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.89A","5y7zA-3zbfA:23.7","5y7zA-3zbfA:12.88"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;LYS A1980;GLU A1997;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 ( 4.7A);None;VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","1.01A","5y7zA-3zbfA:23.7","5y7zA-3zbfA:28.99"],["5Y7Z_A_IREA401_0","CYCLIN-G-ASSOCIATED KINASE","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",7,"LEU A1951;VAL A1959;LYS A1980;GLU A1997;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);None;VGH A3000 ( 4.7A);None;VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","1.01A","5y7zA-3zbfA:23.7","5y7zA-3zbfA:12.88"],["5ZV2_A_LEVA801_2","FIBROBLAST GROWTH FACTOR RECEPTOR 1","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",3,"LYS A1980;LEU A2086;ASP A2102","VGH A3000 ( 4.7A);VGH A3000 (-4.3A);None","0.89A","5zv2A-3zbfA:31.7","5y7zA-3zbfA:28.99"],["6FNM_A_1N1A1001_1","-","3zbf","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","Homo sapiens",8,"VAL A1959;ALA A1978;LYS A1980;MET A2001;ILE A2024;MET A2029;GLY A2032;LEU A2086","None;VGH A3000 (-3.4A);VGH A3000 ( 4.7A);None;None;None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.90A","6fnmA-3zbfA:28.3","5zv2A-3zbfA:16.30"]]